Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
about
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
P2860
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Clinical benefit of 1-year cer ...... a phase III randomised trial.
@en
type
label
Clinical benefit of 1-year cer ...... a phase III randomised trial.
@en
prefLabel
Clinical benefit of 1-year cer ...... a phase III randomised trial.
@en
P2093
P2860
P50
P1476
Clinical benefit of 1-year cer ...... a phase III randomised trial.
@en
P2093
Akira Watanabe
Hideki Origasa
Hisashi Yamanaka
Katsumi Eguchi
Kazuhiko Yamamoto
Masahiro Iwamoto
Naoki Ishiguro
Nobuyuki Miyasaka
Osamu Togo
Shinsuke Yasuda
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-210246
P407
P577
2017-02-02T00:00:00Z